Physician profile
Akbar Rizvi
NPI 1225023948
$5,914.72
in general payments reported to CMS, 2019-2025
58 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $269 · 2021: $164 · 2022: $485 · 2023: $1,371 · 2024: $1,979 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,555 · Long Term Medical Supply Or Device Loan: $682 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,554.81 |
| Long Term Medical Supply Or Device Loan | $681.53 |
| Education | $143.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,010.50 | 2019-2025 | |
| Pfizer INC. | $483.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $443.48 | 2019-2025 | Imfinzi, Lynparza |
| Janssen Biotech, INC. | $329.97 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Medtronic, INC. | $221.36 | 2022-2024 | Osteocool Rf Ablation System, Kyphon Express II Kyphopak Tray |
| E.R. Squibb & Sons, L.L.C. | $219.15 | 2019-2025 | Opdivo |
| Incyte Corporation | $217.68 | 2023-2025 | Jakafi, Monjuvi, Niktimvo |
| Gilead Sciences, INC. | $177.25 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $173.24 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $160.13 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Array Biopharma INC | $137.62 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Celgene Corporation | $136.66 | 2019-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $123.36 | 2019-2020 | |
| Daiichi Sankyo INC. | $121.83 | 2020-2024 | Injectafer, Enhertu, Vanflyta |
| Seagen INC. | $117.54 | 2019-2023 | Tukysa, Padcev, Adcetris |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $114.97 | 2019-2021 | |
| Astellas Pharma US INC | $114.93 | 2023-2025 | Vyloy, Padcev |
| Pharmaessentia USA Corporation | $110.77 | 2022-2023 | Besremi |
| Janssen Pharmaceuticals, INC | $101.98 | 2019-2025 | Xarelto |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Acrotech Biopharma INC. | $82.47 | 2021-2024 | Beleodaq |
| Karyopharm Therapeutics INC. | $69.62 | 2022-2025 | Xpovio |
| Tersera Therapeutics LLC | $57.07 | 2019-2025 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $56.04 | 2020-2023 | Libtayo |
| Kite Pharma, INC. | $54.16 | 2023-2024 | Yescarta |
| Amgen INC. | $54.09 | 2020-2022 | |
| Emd Serono, INC. | $51.21 | 2023-2024 | Tepmetko |
| Geron Corporation | $45.99 | 2025 | Rytelo |
| Glaxosmithkline, LLC. | $45.98 | 2024-2025 | Blenrep, Ojjaara |
| Alnylam Pharmaceuticals INC. | $44.55 | 2024 | Givlaari |
| Sirtex Medical INC | $44.32 | 2019-2024 | Sir-Spheres Microspheres |
| Octapharma USA, INC. | $44.20 | 2019 | |
| Genmab U.S., INC. | $42.87 | 2023-2024 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $40.18 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $39.99 | 2023 | Fotivda |
| Stemline Therapeutics INC. | $37.92 | 2023 | Orserdu |
| Exelixis INC. | $36.22 | 2019-2025 | Cabometyx |
| Adc Therapeutics America, INC. | $34.81 | 2023-2024 | |
| Inari Medical, INC. | $28.22 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Global Blood Therapeutics, INC. | $25.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.77 | 2025 | |
| Sobi, INC | $25.52 | 2022 | |
| Epizyme, INC. | $24.20 | 2022 | |
| Taiho Oncology, INC. | $23.32 | 2025 | |
| Morphosys, US INC. | $22.89 | 2023 | Monjuvi |
| Rigel Pharmaceuticals, INC. | $22.83 | 2023 | Tavalisse, Rezlidhia |
| Tesaro, INC. | $22.82 | 2019 | |
| Eisai INC. | $22.79 | 2023 | |
| Kyowa Kirin, INC. | $21.34 | 2024 | Poteligeo |
| Abbvie INC. | $21.16 | 2024 | |
| Secura Bio, INC. | $20.32 | 2024 | Copiktra |
| Blueprint Medicines Corporation | $20.13 | 2020 | |
| Adaptive Biotechnologies Corporation | $19.67 | 2025 | Clonoseq |
| Myriad Genetic Laboratories, INC. | $16.94 | 2023 | Precisetumor |
| Ipsen Biopharmaceuticals, INC | $16.75 | 2019 | |
| American Regent | $13.68 | 2025 | Injectafer |
| Mylan Institutional INC. | $11.99 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akbar Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.